Can-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.com

Posted by Renee Jackson on Apr 17th, 2024

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research note issued to investors on Sunday. The firm issued a hold rating on the stock.

Can-Fite BioPharma Price Performance

Can-Fite BioPharma stock opened at $2.08 on Friday. The company has a market capitalization of $7.36 million, a PE ratio of -1.16 and a beta of 1.53. Can-Fite BioPharma has a one year low of $1.66 and a one year high of $3.33. The business has a 50 day simple moving average of $2.16 and a 200 day simple moving average of $2.13.

Can-Fite BioPharma (NYSE:CANF – Get Free Report) last posted its earnings results on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. Equities analysts anticipate that Can-Fite BioPharma will post -0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Can-Fite BioPharma

Several institutional investors have recently bought and sold shares of CANF. Schechter Investment Advisors LLC bought a new position in Can-Fite BioPharma in the 4th quarter valued at $44,000. Virtu Financial LLC bought a new position in Can-Fite BioPharma in the 2nd quarter valued at $52,000. Finally, Armistice Capital LLC bought a new position in Can-Fite BioPharma in the 4th quarter valued at $340,000. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.